| Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. | |
| | |
MedLine Citation:
|
PMID: 20086232 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Personalized medicine is health care that tailors interventions to individual variation in risk and treatment response. Although medicine has long strived to achieve this goal, advances in genomics promise to facilitate this process. Relevant to present-day practice is the use of genomic information to classify individuals according to disease susceptibility or expected responsiveness to a pharmacologic treatment and to provide targeted interventions. A symposium at the annual meeting of the Society for Medical Decision Making on 23 October 2007 highlighted the challenges and opportunities posed in translating advances in molecular medicine into clinical practice. A panel of US experts in medical practice, regulatory policy, technology assessment, and the financing and organization of medical innovation was asked to discuss the current state of practice and research on personalized medicine as it relates to their own field. This article reports on the issues raised, discusses potential approaches to meet these challenges, and proposes directions for future work. The case of genetic testing to inform dosing with warfarin, an anticoagulant, is used to illustrate differing perspectives on evidence and decision making for personalized medicine. |
| | |
Authors:
|
Rena Conti; David L Veenstra; Katrina Armstrong; Lawrence J Lesko; Scott D Grosse |
Publication Detail:
|
Type: Journal Article Date: 2010-01-04 |
Journal Detail:
|
Title: Medical decision making : an international journal of the Society for Medical Decision Making Volume: 30 ISSN: 1552-681X ISO Abbreviation: Med Decis Making Publication Date: 2010 May-Jun |
Date Detail:
|
Created Date: 2010-05-21 Completed Date: 2010-06-30 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8109073 Medline TA: Med Decis Making Country: United States |
Other Details:
|
Languages: eng Pagination: 328-40 Citation Subset: IM |
Affiliation:
|
Department of Pediatrics and Center for Health and the Social Sciences, University of Chicago, Chicago, Illinois, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anticoagulants
/
economics,
therapeutic use Cost-Benefit Analysis Decision Making Delivery of Health Care Evidence-Based Medicine / economics* Forecasting Genetic Research Genetic Testing Genetics, Medical Genome, Human Genomics / economics* Humans Individualized Medicine / economics*, trends Pharmacogenetics / economics Research / trends Warfarin / economics, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 81-81-2/Warfarin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Short-term administrations of a combination of anti-LFA-1 and anti-CD154 monoclonal antibodies induc...
Next Document: Assessing the application of tissue microarray technology to kidney research.